Welcome to our dedicated page for Synbio Intl news (Ticker: SYIN), a resource for investors and traders seeking the latest updates and insights on Synbio Intl stock.
Synbio International Inc. (SYIN) issues news that centers on biotechnology, clinically validated nutraceuticals, and AI-driven medical diagnostics. Its recent announcements highlight developments in AI-based facial analysis for depression screening, strategic partnerships, leadership appointments, and capital planning within the healthcare and health information services space.
One key theme in Synbio’s news flow is its collaboration with FacialDx, Inc. The company reports on a Clinical Trial License Agreement and subsequent Share Purchase and Warrant Agreements that give Synbio an equity stake in FacialDx and a defined role in conducting clinical trials for AI-powered facial analysis software used in depression screening. News items describe the establishment of a Joint Trial Oversight Committee to guide trial design, data integrity, and regulatory alignment, with an emphasis on supporting potential FDA submissions.
Synbio’s press releases also cover changes in leadership that it views as important for clinical and financial oversight. These include the appointment of a Medical Director with extensive clinical trial experience to oversee a feasibility trial of facial analysis depression screening software, and the appointment of a Chief Financial Officer responsible for financial operations and compliance with U.S. SEC and OTC Markets requirements.
Investors and observers can use this news page to follow updates on Synbio’s clinical validation efforts, strategic agreements with FacialDx, governance and board changes, and discussions of funding approaches related to its clinical and commercial objectives. Recurring topics include AI-driven mental health screening, trial governance structures, equity participation in partner technologies, and the company’s stated focus on aligning scientific rigor with shareholder value considerations.
Synbio International (OTC: SYIN) appointed Dr. Nick Vatakis, MD as Medical Director and added him to its Board of Directors on October 22, 2025. Dr. Vatakis brings nearly 30 years of clinical and research experience, having served as principal investigator on over 200 clinical trials and previously founding and serving as CMO of a clinical research organization.
He will oversee the design and execution of Synbio’s upcoming feasibility trial for its AI-driven facial analysis depression screening software, with responsibility for ethical, medical, and scientific standards. Management states the appointment is intended to strengthen clinical rigor, regulatory credibility, and commercialization efforts.
Synbio International (OTC: SYIN) executed a Share Purchase Agreement and Warrant Agreement with FacialDx on Oct 8, 2025, acquiring 100,000 Class A shares and committing US$200,000 across four tranches over 12 months. Synbio also retains the right to convert up to US$2.5M of future clinical trial expenditures into FacialDx equity at today’s valuation. FacialDx received a warrant to buy 30,000,000 Synbio shares at $0.001 per share exercisable upon FDA approval. A Joint Trial Oversight Committee will govern clinical design and reporting to support FDA submission and commercialization.
Synbio International (OTC: SYIN) has appointed Ms. Desiree Cain, CPA, MBA as Chief Financial Officer and Board Member, effective immediately. Ms. Cain brings over 25 years of experience in corporate finance, accounting, and strategic growth management.
As CFO, she will lead financial operations, including accounting, reporting, and compliance with SEC and OTC Markets requirements. Her role will focus on developing governance frameworks and risk management strategies to align with public company best practices.
Synbio International Inc. (SYIN) has secured rights to conduct clinical trials for an innovative AI-powered depression screening technology called NIMS (Non-invasive Mental Screening). The technology, developed by FacialDx Inc., analyzes facial features through mobile or desktop devices to detect depressive symptoms.
The clinical trials will begin with a retrospective feasibility study, followed by a larger prospective validation trial if successful. NIMS utilizes advanced AI and machine learning algorithms to provide instant, cost-effective screening results, built on over 40 years of research by Dr. Todd Frisch.
The commercial strategy includes:
- Integration into clinical settings for medical practitioners
- Corporate partnerships in aviation, law enforcement, and emergency services
- Potential direct-to-consumer applications
With the U.S. medical device market projected to reach $6.45 billion by 2029, NIMS aims to revolutionize mental health screening by providing objective, data-driven analysis to complement traditional diagnostic methods.
FAQ
What is the current stock price of Synbio Intl (SYIN)?
What is the market cap of Synbio Intl (SYIN)?
